• 27.09.2019 – 08:01

  Merck KGaA

  Abstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers

  Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...

  more

• 25.03.2019 – 12:04

  Merck KGaA

  MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland

  Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...

  more

• 11.09.2018 – 14:31

  Merck KGaA

  BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

  Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...

  more